Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Shares of CRISPR Therapeutics AG (CRSP ... Going by the price targets, the mean estimate of $81.96 indicates a potential upside of 62.8%. The mean estimate comprises 24 short-term price targets with a ...

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

CRISPR gene editing can have unforeseen consequences on the structure of chromosomes, says the University of Zurich.

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR ... the estimated mean monthly attack rate was 0.70 ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Casgevy was the first drug to be licensed based on CRISPR, which earned its discoverers a Nobel Prize in 2020. The one-shot therapy is an ex vivo application of the technology, meaning that bone ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up ...